Bimodal EGFR signaling in glioblastoma
胶质母细胞瘤中的双峰 EGFR 信号转导
基本信息
- 批准号:10544555
- 负责人:
- 金额:$ 41.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-01 至 2026-12-31
- 项目状态:未结题
- 来源:
- 关键词:AdultAnimal ModelAtlasesAutomobile DrivingBiologicalCell ProliferationCellsClinicalCytoskeletonDataDimerizationEGFR Gene AmplificationEGFR inhibitionEpidermal Growth Factor ReceptorFDA approvedGlioblastomaGliomaHumanInvadedLigandsMAP3K7 geneMAP3K7IP1 geneMalignant NeoplasmsMalignant neoplasm of brainMediatingMembraneModalityModelingMutationOncogenesOncogenicPIK3CG genePathway interactionsPatternPharmaceutical PreparationsPrognosisProliferatingProteinsRegulationReportingRoleSignal PathwaySignal TransductionTertiary Protein StructureTestingThe Cancer Genome AtlasTherapeuticTissuesTransactivationTumor ExpansionTumor Suppressor ProteinsUp-Regulationblood-brain barrier permeabilizationefficacy evaluationepidermal growth factor receptor VIIIimprovedmalignant phenotypemouse modelmutantnoveloverexpressionrho GTP-Binding Proteinstumortumor progression
项目摘要
Abstract
Glioblastoma (GBM) is the most common primary brain cancer in adults. EGFR is expressed in the majority of
GBMs and aberrant EGFR signaling is a major driver of the malignant phenotype. Although the EGFR is
considered a prime oncogene in GBM, TCGA analysis indicates that in EGFR amplified GBMs, EGFR ligands
are tumor suppressive. Our preliminary data also suggest that ligand-activated EGFR is tumor suppressive.
The tumor suppressive effects of ligand-activated EGFR result form an unexpected suppression of invasion.
We propose that constitutive and ligand-dependent EGFR wild type signaling triggers distinct signaling
pathways. Thus, constitutive EGFR signaling promotes invasion while ligand-activated EGFR signaling turns
on proliferation and turns off invasion. We elucidate mechanisms underlying EGFR regulation of invasion and
identify BIN3, a protein known to influence the cytoskeleton, as a key suppressor of GBM invasion. We also
identify the mechanisms and biological significance of ligand-activated EGFR mediated glioma cell
proliferation. We examine the relative contribution of proliferation and invasion to tumor size and prognosis in
GBM. An improved understanding of mechanisms that drive GBM invasion is critical to improved treatment.
Furthermore, we identify tofacitinib as a drug that can activate the tumor suppressor function of EGFR by
increasing EGFR ligand, upregulating BIN3 and suppressing GBM invasion. Tofacitinib is a clinically available
and FDA approved drug. Our model holds true for GBMs that express EGFR wild type or the mutant
EGFRvIII. In Specific Aim 1: We elucidate the role of RTK transactivation in driving invasion or proliferation.
We test the hypothesis that constitutive EGFR signaling promotes EGFR invasiveness whereas ligand-induced
EGFR signaling blocks it. Constitutive EGFR signaling leads to activation of Met leading to increased
invasiveness. We also identify a TAB1-TAK1-NF- B pathway that drives GBM invasion. Ligand-activated
EGFR signaling leads to Axl activation and proliferation and decreased GBM invasiveness. In Specific Aim 2:
we uncover mechanisms used by EGFR to suppress invasiveness of GBM cells. We test the hypothesis that
BIN3 is a major negative regulator of invasion. Ligand-induced EGFR activity upregulates BIN3 and
suppresses invasion. We examine the expression patterns of BIN3, BIN3 partners, EGFR and other RTKs
networks in GBM. In Specific Aim 3 we examine the biological effects of constitutive vs. ligand induced
EGFR–RTK-BIN3 signaling on GBM invasion in an orthotopic mouse model and examine tofacitinib as a
treatment that specifically inhibits GBM invasion in ligand-poor GBMs. .
摘要
胶质母细胞瘤(GBM)是成人最常见的原发性脑癌。EGFR在大多数细胞中都有表达
基底膜和异常的EGFR信号是恶性表型的主要驱动因素。尽管EGFR是
被认为是GBM的主要癌基因,TCGA分析表明在EGFR扩增的GBM中,EGFR配体
对肿瘤有抑制作用。我们的初步数据还表明,配体激活的EGFR具有肿瘤抑制作用。
配体激活的EGFR的肿瘤抑制作用产生了意想不到的侵袭抑制。
我们认为,构成和配体依赖的EGFR野生型信号触发不同的信号转导
小路。因此,结构性的EGFR信号促进侵袭,而配体激活的EGFR信号转而
关于核扩散和关闭入侵。我们阐明了EGFR调节侵袭性和
确定BIN3,一种已知影响细胞骨架的蛋白质,是GBM入侵的关键抑制因子。我们也
配体激活的EGFR介导的胶质瘤细胞的作用机制及其生物学意义
扩散。我们研究了增殖和侵袭对肿瘤大小和预后的相对贡献。
GBM。更好地了解推动GBM侵袭的机制是改进治疗的关键。
此外,我们确定tofacitinib是一种可以通过以下方式激活EGFR的肿瘤抑制功能的药物
增加EGFR配体,上调BIN3,抑制GBM侵袭。托法替尼是一种临床可用的
以及FDA批准的药物。我们的模型适用于表达EGFR野生型或突变体的GBM
EGFRvIII.在特定的目标1:我们阐明了RTK反式激活在驱动侵袭或增殖中的作用。
我们验证了这样的假设,即结构性的EGFR信号促进EGFR的侵袭性,而配体诱导
EGFR信号会阻止它。结构性EGFR信号导致Met激活,导致Met升高
侵犯性。我们还发现了一条TAB1-TAK1-NF-B通路,驱动GBM的侵袭。配基激活
EGFR信号转导导致Axl活化和增殖,降低GBM侵袭力。具体目标2:
我们揭示了EGFR用来抑制GBM细胞侵袭性的机制。我们检验了这一假设
BIN3是侵袭的主要负性调节因子。配体诱导的EGFR活性上调BIN3和
抑制入侵。我们检测了BIN3、BIN3伙伴、EGFR和其他RTK的表达模式
GBM中的网络。在特定的目标3中,我们研究了结构性与配体诱导的生物学效应。
EGFR-RTK-BIN3信号转导在小鼠原位肾小球系膜侵袭中的作用
特异性抑制缺乏配体的GBM侵袭的治疗。。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
AMYN HABIB其他文献
AMYN HABIB的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('AMYN HABIB', 18)}}的其他基金
The role of Nrf2 in mediating resistance to EGFR inhibition in glioblastoma
Nrf2 在介导胶质母细胞瘤对 EGFR 抑制的抵抗中的作用
- 批准号:
10404075 - 财政年份:2020
- 资助金额:
$ 41.39万 - 项目类别:
The role of Nrf2 in mediating resistance to EGFR inhibition in glioblastoma
Nrf2 在介导胶质母细胞瘤对 EGFR 抑制的抵抗中的作用
- 批准号:
10615766 - 财政年份:2020
- 资助金额:
$ 41.39万 - 项目类别:
Interactions between inflammatory and oncogenic signaling pathways in GBM
GBM 炎症和致癌信号通路之间的相互作用
- 批准号:
8735239 - 财政年份:2014
- 资助金额:
$ 41.39万 - 项目类别:
Interactions between inflammatory and oncogenic signaling pathways in GBM
GBM 炎症和致癌信号通路之间的相互作用
- 批准号:
10266003 - 财政年份:2014
- 资助金额:
$ 41.39万 - 项目类别:
Interactions between inflammatory and oncogenic signaling pathways in GBM
GBM 炎症和致癌信号通路之间的相互作用
- 批准号:
9339563 - 财政年份:2014
- 资助金额:
$ 41.39万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 41.39万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 41.39万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 41.39万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 41.39万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 41.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 41.39万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 41.39万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 41.39万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 41.39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 41.39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists